Goodwin Procter advised AlgoTx on the deal. AlgoTx announced its €20 million Series B. AlgoTx develops novel solutions for complex pain. Their lead program, ATX01, targets highly…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
